BC.GAME Esports Signs CS Major Champion electronic
CSGO roster and content operations upgraded, offering more interactive experiences for global fans BELIZE CITY, Belize, Oct. 19, 2025 /PRNewswire/ — BC.GAME... Read more.
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
CHENGDU, China , Oct. 19, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) announced that at the 2025 European... Read more.
Redefines the Future of TV: SKYWORTH Unveils All-New Matte Screen Ultra TV Series at the 138th Canton Fair
SHENZHEN, China, Oct. 19, 2025 /PRNewswire/ — From October 15 to 19, 2025, SKYWORTH showcased its all-new Matte Screen Ultra TV series, alongside a selection... Read more.
Xinhua Silk Road: Financial Street Forum annual conference to be held on Oct. 27-30 in Beijing
BEIJING, Oct. 19, 2025 /PRNewswire/ — The annual conference of Financial Street Forum 2025 will be held on October 27-30 in Beijing. Over 400 delegates from... Read more.
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
SHANGHAI and HONG KONG, Oct. 19, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage... Read more.
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
SHANGHAI, Oct. 20, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies,... Read more.
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
– The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation... Read more.
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
SHANGHAI, Oct. 19, 2025 /PRNewswire/ — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed... Read more.
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups... Read more.
iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
Findings published in Nature Biomedical Engineering and presented at ESMO 2025 validate iOncologi’s Universal Immune Fortifying RNAs (UNIFYRs™) as a new... Read more.